TrialPath
Recruiting

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

NCT07428447 · CND Life Sciences
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
Eligibility criteria
Inclusion Criteria: * Age 50-85 years old * Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR * Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here." * Willing to participate in all study procedures * Able and willing to provide written informed consent Exclusion Criteria: * Under age 50, Over age 85 * Clinical evidence of severe peripheral vascular disease * Clinically active coronary artery or cerebrovascular disease * Participant is currently on anticoagulant or dual anti-platelet therapy * Alcoholism * Allergic reaction to local anesthesia * History of or increased risk for impaired wound healing, scarring, or keloid formation * Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise * History of other neurodegenerative disorder or evidence of neurological co-pathology * Abnormal DaTscan * Participant is currently receiving treatment with carbidopa-levodopa for PD * Isolated focal tremors (head, voice) * Task-specific tremor (e.g., primary writing tremor) * Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET * Sudden onset and step-wise deterioration * Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.
Study design
Enrollment target: 300 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-02-18
Estimated completion: 2029-02
Last updated: 2026-11-19
Primary outcomes
  • • Quantity of P-SYN in skin (From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24)
  • • Rate of Phenoconversion (From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24)
Sponsor
CND Life Sciences · other
With: National Institute of Neurological Disorders and Stroke (NINDS)
Contacts & investigators
ContactJeannie Director of Clinical Research · contact · ClinicalResearch@cndlifesciences.com · 480-434-6446
All locations (11)
CND Clinical Research CenterRecruiting
Scottsdale, Arizona, United States
Movement Disorders Center of ArizonaRecruiting
Scottsdale, Arizona, United States
University of California Irvine HealthNot Yet Recruiting
Irvine, California, United States
Cedars-Sinai Medical CenterNot Yet Recruiting
Los Angeles, California, United States
Neurology OneRecruiting
Orlando, Florida, United States
University of Kansas Medical CenterRecruiting
Kansas City, Kansas, United States
Norton HealthcareRecruiting
Louisville, Kentucky, United States
Quest Research InstituteRecruiting
Farmington Hills, Michigan, United States
Veracity Neurosciences LLCRecruiting
Memphis, Tennessee, United States
Vanderbilt University Medical CenterRecruiting
Nashville, Tennessee, United States
Baylor College of MedicineRecruiting
Houston, Texas, United States
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease · TrialPath